This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Investors Overreact to Opexa Finding Scant Interest for Failed Multiple Sclerosis Drug

Opexa should have discontinued Tovaxin based on these poor study results. Instead the company spent the past three years picking apart the data retrospectively to find subsets of patients where Tovaxin performed better.

In January 2011, Opexa announced plans to begin a phase III study of Tovaxin in relapsing-remitting MS. That study was never started. Instead, in November 2011, Opexa shifted gears and decided to conduct a new phase II study of Tovaxin in patients with secondary progressive MS -- a more severe and harder-to-treat form of the disease.

In May 2012, Opexa changed the name of the drug to Tcelna, a ruse to help investors forget about the drug's history of failure.

The phase II study of Tcelna in secondary-progressive MS only started last fall and Opexa doesn't enough cash to complete it.

As Biogen Idec (BIIB - Get Report) waits to hear from the FDA on the approval of its MS pill BG-12 -- a drug expected to be a commercial blockbuster, German Merck decided the time is right to option a MS vaccine with a long history of failure.

Good luck with that.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BIIB $401.71 0.00%
OPXA $0.43 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs